Pre-operative albendazole therapy for hydatid cyst

Area of Science:

• Medical Parasitology
• Surgical Oncology
• Pharmacology

Background:

• Surgical treatment for hydatid cyst infections can lead to recurrence in approximately 10% of cases.
• The potential benefit of perioperative chemotherapy in preventing hydatid cyst recurrence remains underexplored.

Purpose of the Study:

• To investigate the efficacy of preoperative albendazole in reducing viable protoscoleces in hydatid cysts.
• To assess the impact of preoperative albendazole duration on cyst viability.

Main Methods:

• Sixteen patients diagnosed with Echinococcus granulosus underwent treatment with albendazole (10 mg/kg).
• Patients received varying durations of preoperative albendazole, ranging from 1 to 4 weeks or more.
• Cyst contents were examined during surgery for the presence of viable protoscoleces.

Main Results:

• Of fourteen patients receiving albendazole for one month or longer preoperatively, only one showed viable protoscoleces (with questionable compliance).
• In contrast, both patients receiving only one to three weeks of preoperative albendazole had viable disease at surgery.
• A minimum one-month preoperative course of albendazole appears effective in eliminating or significantly reducing protoscoleces.

Conclusions:

• A one-month preoperative course of albendazole can effectively 'sterilize' hydatid cysts by killing protoscoleces.
• This preoperative chemotherapy approach may reduce the risk of hydatid cyst recurrence following surgical management.